The FDA’s Office of Prescription Drug Promotion (OPDP) wants to find out how patients and physicians weigh the tradeoffs between risks and benefits when starting a new prescription drug. What characteristics influence treatment choices and how do people reach the decision for one drug over another? The OPDP will be answering these questions through a new study.
The study will focus on type 2 diabetes and psoriasis, splitting 800 patients and 800 physicians who have or specialize in those diseases to compare the preferences of the two groups. Participants will be asked to make specific choices based on profiles of fake prescription drugs in a process that will take 20 minutes.